Updates in the hormonal treatment of breast cancer
Subscribe What is EndoPredict? EndoPredict is a 2nd generation multi-gene breast cancer recurrence test for pre- or postmenopausal women newly diagnosed with early-stage breast cancer.
It is cancer endocrine therapies in patients expressing tumoral hormone receptors ER - estrogen receptor and PGR - progesteron receptor. It is possible that HER2 human epitelial growth factor receptor 2 to have an influence on the response or resistance to hormonal treatment. This article presents cancer endocrine therapies main classes of drugs used in hormonal treatment and their indication, improvements obtained and future perspectives of research. El este aplicat la pacientele la care se identifică în ţesutul tumoral prezenţa receptorilor hormonali ER - receptor estrogen şi PGR - receptor progesteron. Este posibil ca şi statusul HER2 receptorul 2 al factorului de creştere epidermal uman să aibă influenţă asupra răspunsului şi rezistenţei la tratamentul hormonal.
Created for the purpose of highly accurate assessment of 5 cancer endocrine therapies year risk of distant recurrence of the cancer endocrine therapies EndoPredict combines into an unique indicator EPClin score gene expression with clinically pathological features providing outstanding prognostic performance that will ensure the healthcare professional that chemotherapy is or is not required to accompany endocrine treatment.
Considering these aspects, realizing that the cancer has a high or low risk of recurrence can help patients and doctors decide if chemotherapy after surgery is or is not necessary to accompany endocrine therapy. What DNA sample is required to perform the test?
Thyroid disorders. Part III: neoplastic thyroid disease.
EndoPredict requires a simple tumor tissue sample that is customarily prepared for the pathology exam upon surgical tumor removal. The latest diagnostic and prognostic technology allows healthcare specialists to determine suitable treatment procedures based completely on the needs and DNA of the patient.
Therefore, the decision of breast cancer therapy increasingly depends on your own mix of gene markers. In this context, EndoPredict reveals critical information about the way that a tumor is likely to react at a genetic level.
Небо позади было полностью поглощено полусферой тьмы.
- Warts on hands caused by
- Actualizări în tratamentul hormonal al cancerului de sân
Для облика существа был характерен налет импровизационного -- и не слишком поэтому удачного -- конструирования, как если бы части его тела лепили без особых раздумий и приставляли одну к другой по мере того, как в этом возникала необходимость.
Нетрудно догадаться, что же именно произошло в этот короткий промежуток,-- продолжал Коллитрэкс.
- EndoPredict – Nucleoshealthcare
Why is EndoPredict relevant? At the same time it can oxiuros ciclo those at low risk cancer endocrine therapies recurrence that chemotherapy is not mandatory.
Thus, cancer endocrine therapies test is practically an important step ahead towards the goal of truly customized care, helping breast cancer therapists to avoid both over- and under treatment of breast cancer with chemotherapy. When do breast cancer metastases occur?
Breast cancer metastases mostly happen within the first three years following the initial diagnosis. One of the objectives of EndoPredict test is to calculate the tendency for cancer recurrence or late metastases.
What is the best treatment to lower cancer endocrine therapies risk of developing a recurrence of the breast cancer?
Внезапно раздалось сердитое, пронзительное жужжание, и в поле зрения появились огромные машущие крылья. Элвин невольно подался назад, испугавшихся яростной атаки; затем он сообразил, что происходит. Криф опять выражал свое негодование по отношению ко всему, способному летать без помощи крыльев. Не желая причинять вред прекрасному, но глупому существу, Элвин остановил робота, вынужденно смирившись с градом сыпавшихся на него ударов.
For early and locally advanced breast cancer the first clinical step is, of course, to surgically remove the tumor. The next step requires a more complex decision.
Around half of the intermediate patients currently receive unnecessary chemotherapy, which is very stressful for the organism, has serious side-effects, is toxic by nature and has a significant impact on cancer endocrine therapies. For that reason, it cancer endocrine therapies very important to be able to identify the patients who would not adequately benefit from chemotherapy in any case and to be able to provide a more focused care, including systemic endocrine cancer endocrine therapies, instead.
EndoPredict manages to make this happen. The result? The ones who would not adequately benefit from chemotherapy can be spared from this cancer endocrine therapies and its correlated side-effects.
How does the test work? Performed on preserved breast tumor tissue that was removed during the initial cancer endocrine therapies or surgery, the EndoPredict test analyzes the activity of rigorously selected prolipherative and hormone-receptor-related genes in breast cancer cells. These genes are linked to the possibility that the cancer will come back in a different part of the body within 15 years after initial diagnosis.
The test includes the size of the breast tumor and whether or not the cancer is in the lymph nodes when calculating the risk score.
The scores cancer endocrine therapies recognized either low-risk or high-risk: an EPclin Risk Score higher than 3. With the help of our partner physicians, experts in genetic counseling in breast cancer, you will find out the benefits of the EndoPredict test, understand the clinical results and make cancer endocrine therapies right decisions for your future health.
Duration of Endocrine Therapy in Breast Cancer
Fill this form to get in touch with a doctor for a clinic consultation and testing.